Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Total 13F shares
-
21,557,623
-
Share change
-
+21,557,623
-
Total reported value
-
$1,000,339,109
-
Price per share
-
$46.81
-
Number of holders
-
41
-
Value change
-
+$1,000,339,111
-
Number of buys
-
41
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q2 2020
As of 30 Jun 2020,
ADC Therapeutics SA - Common Shares (ADCT) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
21,557,623 shares.
The largest 10 holders included
Redmile Group, LLC, FMR LLC, BAKER BROS. ADVISORS LP, Magnetar Financial LLC, Grosvenor Holdings, L.L.C., JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., PRICE T ROWE ASSOCIATES INC /MD/, MPM Oncology Impact Management LP, and HILLHOUSE CAPITAL ADVISORS, LTD..
This page lists
41
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.